Get notified when TENX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure Of Cfo (new) — Interim CFO Thomas McGauley resigned effective May 10, 2026, though he will continue consulting through month-end to support the transition.
Tenax Therapeutics appoints Thomas R. Staab as CFO with $428K salary, 450K stock options
Filed April 22, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
high
Thomas R. Staab appointed CFO effective May 11, 2026, bringing 25+ years healthcare finance experience including prior CFO roles at LENSAR, BioCryst Pharmaceuticals, and Inspire Pharmaceuticals.
Item 5.02 verify on EDGAR → -
high
Staab's compensation package includes $428,000 base salary, 45% target bonus, 10,000 restricted stock units vesting over one year, and options for 450,000 shares vesting over four years with one-year cliff.
Item 5.02 verify on EDGAR → -
medium
Interim CFO Thomas McGauley resigned effective May 10, 2026, one day before Staab's start date. McGauley will continue consulting through at least end of May to support transition and complete Q1 10-Q filing.
Item 5.02 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ISNR 10-Q) is open in full — no account needed.
Partner
Trade TENX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify